Data supports expanding indications for bioelectronics platform

[fa icon="calendar"] November 11, 2016 - by : Company News

Company News

Company set to present data from two preclinical R&D programs at the Society for NeuroScience's Annual Conference 

Lexington, KY – Nexeon Medsystems, Inc. (“Nexeon” or “the Company”) will present the findings of two preclinical programs that are exploring additional applications of neurostimulation: dysphagia and overactive bladder (OAB). These studies were funded by Small Business Innovative Research (SBIR) grants based on ingenuity in addressing present-day clinical unmet needs.  Dr. Navid Khodaparast will represent the Company as the contributing research scientist for both programs.  


“Nexeon is developing a new future for patients who suffer from neurological diseases,” said William Rosellini, Nexeon Chairman and CEO. “Preclinical research is difficult to translate to humans, but support from the NIH helps us understand the disorders, improve the technology, and expand the clinical indications so that one day, a patient with a neurological disease can be restored to a normal state.”

Dr. Khodaparast is leading Company collaborations with Dr. Paul Yoo at the University of Toronto.  Together, the research team completed a 12-week study that demonstrated the viability of using a wirelessly-powered, implantable neurostimulation device (seen in figure) for long-term activation of the tibial nerve.  These preclinical findings support a potential therapeutic option for patients who suffer from OAB, but cannot or do not wish to subscribe to regular office visits for external tibial nerve stimulation.  

Dr. Khodaparast is also collaborating with Dr. Teresa Lever at the University of Missouri.  Their aim is to stimulate the superior laryngeal nerve, a branch of the vagus nerve, to improve swallow function in an animal model of neurogenic dysphagia.  They anticipate completing this experiment in early 2017 with the goal of translating this novel therapy for use in patients who suffer from amyotrophic lateral sclerosis, Parkinson’s disease, or stroke.  


Referenced Presentations:!/4071/presentation/25104

Grant#: 1R43DK101147-01

Institute: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)!/4071/presentation/31747

Grant#: 1R43DC015192-01

Institute: National Institute on Deafness and Other Communication Disorders (NIDCD)



Are you a SPARC researcher?

Do you have an idea in the field of neurostimulation or bioelectronics?  

If so, we want to support your research.  Connect with us to learn more!

Request info about our collaboration opportunities


About Nexeon MedSystems: Nexeon is a bioelectronics company developing and manufacturing medical devices and the software platforms that support the remote management of these devices.  The Company has a portfolio of intellectual property focused on active implantable devices.  For more information, visit

Forward-Looking and Cautionary Statements: Statements in this press release that are not strictly historical may be “forward-looking” statements, which involve risks and uncertainties, and Nexeon undertakes no obligation to update any such statements to reflect later developments. These risks and uncertainties include Nexeon’s ability to successfully complete on the terms and conditions contemplated, and the financial impact of, its strategic portfolio repositioning actions, as well as economic and currency conditions, market demand, pricing, protection of intellectual property, and competitive and technological factors, among others, as set forth in Nexeon’s subsequent reports filed with the SEC.

Topics: Clinical Trials, R&D

Subscribe to Email Updates